The study investigates 177Lu-CTR-FAPI, a radiopharmaceutical targeting FAP, in patients with advanced metastatic gastrointestinal malignancies. Given the high unmet medical need in this patient population, successful outcomes could position 177Lu-CTR-FAPI as a novel therapeutic option in a competitive landscape dominated by traditional chemotherapy and emerging targeted therapies. The market for advanced GI malignancies is substantial, with increasing incidences of pancreatic and colorectal cancers. The trial's single-arm design may limit comparative efficacy claims, necessitating further studies for broader market acceptance. Diligence should focus on the safety profile and potential for combination therapies, as well as regulatory pathways in key markets.